News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2020

June

Media Release / Jun 19, 2020

Statement from Novartis on AVXS-101 filing with Health Canada

Read More
Media Release / Jun 16, 2020

Long-term, relapse-free survival data for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery presented at ASCO20

Read More

May

Media Release / May 27, 2020

Novartis in Canada responds to COVID-19 with commitments in key areas

Read More

April

Media Release / Apr 27, 2020

Novartis in Canada initiates Community Strong COVID-19 response program

Read More
Media Release / Apr 16, 2020

Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment

Read More
Media Release / Apr 15, 2020

Novartis recognized as one of the Best Workplaces™ in Canada

Read More

March

Media Release / Mar 17, 2020

Coronavirus disease (COVID-19) update

Read More
Media Release / Mar 03, 2020

Novartis receives Health Canada approval for MayzentTM (siponimod) to treat secondary progressive multiple sclerosis with active disease

Read More
2019

December

Media Release / Dec 16, 2019

British Columbia lists Tafinlar® plus Mekinist® for adjuvant treatment of melanoma patients with BRAF V600 mutation and lymph node involvement1

Read More
Media Release / Dec 12, 2019

Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)1

Read More